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ThreenovelstablePt(III)complexeswithdistortedoctahedralstructureand(dz2)
1 groundstatehavebeenobtainedinthecourseof
Pt(II)-hematoporphyrinIX((7,12-bis(1-hydroxyethyl)-3,8,13,17-tetramethyl-21H-23H-porphyn-2,18-dipropionicacid),Hp)in-
teraction in alkaline aqueous medium and aerobic conditions. A redox interaction also takes place together with the complexation
processleadingtotheformationofPt(III)speciesandorganicradicals.Theprocessesinthereactionsystemandthestructureofthe
complexes formed cis-[Pt(III)(NH3)2(Hp−3H)(H2O)2]·H2O1, [Pt(III)(Hp−3H)(H2O)2]·H2O2, and [Pt((O,O)Hp−2H)Cl(H2O)3]
3, were studied by UV-Vis, IR, EPR and XPS spectra, thermal (TGS, DSC), potentiometric and magnetic methods. The newly syn-
thesized complexes show promising cytotoxic activity comparable with that of cis-platin in in vitro tests against a panel of human
leukemia cell lines. The observed cytotoxicity of the complex 2 against SKW-3 cells (KE-37 derivative) is due to induction of cell
death through apoptosis.
Copyright © 2007 G. Gencheva et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Since the discovery of the cytotoxic activity of cis-platin (cis-
diamminedichloroplatinum(II)) [1], the eﬀorts have been
directed towards elucidation of the molecular mechanism of
its action [2–4] and synthesis of new platinum compounds
with improved antitumor activity [5] and side eﬀects. Till
now, a large library of platinum complexes has been syn-
thesized and their antitumour activity has been examined
but only cis-platin, carboplatin, and oxaliplatin have received
a worldwide approval and achieved routine clinical use. At
present, the cytotoxicity of cis-platin and other platinum(II)
complexes is thought to originate from their interaction with
DNA as well as with non-DNA targets [2, 6–8], and sub-
sequent induction of cell death through apoptosis and/or
necrosis [9, 10]. Despite its wide application as an antitu-
mor drug for treatment of diﬀerent kinds of cancer, cis-
platin has several inherent shortcomings as limited solubil-
ity and side toxic eﬀects including nausea, nephrotoxicity,
vomiting, and so forth [11]. In addition, many tumors dis-
play natural resistance to cis-platin and others develop re-
sistance after the initial treatment [12]. Thus the applica-
tion of the drug is restricted to a relatively narrow class of
tumors and the eﬀorts were focused on the design of new
platinum compounds with broader spectrum of antitumor
activity and improved pharmacological properties with re-
spect to toxicity and resistance. Several complexes struc-
turally related to cis-platin, such as oxaliplatin and carbo-
platin, nedaplatin (Japan), lobaplatin (China), heptaplatin
(South Korea) [5, 13, 14], are currently in clinical trials2 Metal-Based Drugs
and use, but till now they have not demonstrated signiﬁ-
cant advantages over cis-platin. It seems possible that the
complex structural analogs of cis-platin designed on the
basis of structure-activity relationships [15] could scarcely
oﬀer serious advantages over the existing drugs. Analyzing
the current status of the platinum-based antitumor drugs
[5], it can be concluded that the search for improved plat-
inum antitumor agents continues [16–18] mainly in direc-
tion to modulate the DNA-binding mode and DNA damage
by changing the model structure of the platinum drug used.
One of the strategies for a design of new platinum anti-
tumor compounds is to combine platinum(II) moiety with
proper carrier groups, and thus to target selectively the tu-
mor cells. An example of this approach is the synthesis of
porphyrin-platinum complexes. The porphyrin ligands pro-
vide preferable accumulation in neoplastic tissue [19–21],
whereas platinum complexes such as cis-platin and carbo-
platinpenetrateunselectively[3,17].Besides,theporphyrins
and, in particular, hematoporphyrin derivatives (HpD) are
known with their widespread application in the photo-
dynamic therapy and diagnosis [22, 23]. During the last
decades, a considerable interest has been paid to the synthe-
sis and characterization of Pt(II) complexes with hemato-
porphyrin IX and hematoporphyrin-type ligands [21, 24–
28]. The porphyrin ligand could be coordinated to Pt(II)
as a bidentate or tetradentate one by the pyrrole nitrogens
[24, 25]. Recently, the preparation and structural charac-
terization of a large number of platinum-porphyrin conju-
gates have been discussed [21, 26–29]. In these compounds,
platinum(II) fragment is attached to the propionic acid side
chains out of the porphyrin macrocycle. The cytostatic activ-
ity of these platinum(II) porphyrin conjugates towards dif-
ferent kinds of mammary and bladder cancer cell lines has
been tested in dark and after irradiation. A high activity was
reported, especially for the water-soluble conjugates [27, 28].
Other factor of great importance for the enhancement
of the antitumor activity and circumvention of the drug re-
sistance is the oxidation state of platinum in the antitumor
drug. The higher oxidation platinum complexes possess in-
creased opportunity to be delivered to the cellular target as
an active agent. It is well known that in physiological media,
platinum(IV) anticancer agents are easily reduced to active
platinum(II) products [5, 18]. An advantage of the Pt(IV)
complexes is their lower reactivity which decreases the loss
of the active drug and the incidence of the side reactions. In
addition, the axial ligands in the octahedral platinum (IV)
complexes could alter the lipophilicity and the redox poten-
tial of the complex, and thus improve the cellular uptake and
control of the reduction rate.
In the present paper, we propose a new approach for de-
sign of cytotoxic agents with improved properties, namely to
combine platinum in the unusual oxidation state +3 with
a proper ligand system which could stabilize this oxida-
tion state and serve as a speciﬁc carrier group. This ap-
proach is based on the idea for the intermediate behav-
ior of Pt(III) complexes between the complexes of Pt(II)
and Pt(IV) with respect to kinetic inertness and ther-
modynamic stability. Hematoporphyrin IX was used as a
ligand system. As a further development of our studies
on the synthesis of stable Pt(III) complexes [29–31]w i t h
proper ligand systems [32–34], we have investigated the
Pt(II)-hematoporphyrin IX interaction in aqueous-alkaline
medium and aerobic conditions on light. Three stable oc-
tahedral Pt(III)-hematoporphyin complexes have been syn-
thesized and structurally characterized by spectroscopic and
magnetic methods. The cytotoxic activity study showed that
despite the violation of the empirical structure—activity re-
lationship rules [15], the complexes show a promising cyto-
toxicitycomparablewiththatofcis-platin.Althoughthehigh
antitumor activity of mixed oxidation Pt(II)–Pt(III) poly-
meric complexes of “platinum blues” type was recognized
long ago [35], this is the ﬁrst report on the cytotoxic eﬀect
of stable monomer Pt(III) species.
2. MATERIALS AND METHODS
All reagents and solvents were of analytical grade and were
obtained by commercial sources and used without further
puriﬁcation. A sample of 0.030g (0.050mmol) Hp was dis-
solved by stirring in 8mL 5 × 10
−2 M KOH (0.40mmol)
and a pH value of 11.0–11.5 was ﬁnally obtained. A cis-
diammine(diaqua)platinum(II) hydroxide solution was pre-
pared by stirring cis-platin (0.2mmol, 0.060g for the com-
plex 1; and 0.1mmol, 0.030g for the complex 2)w i t h1 . 9 5
molar equivalents of AgNO3 in water (5mL). The mixtures
were kept in dark for 24 hours and the AgCl formed was
then removed by a centrifuge. Aqueous solution of K2PtCl4
(1.10−2 M) was used for the synthesis. The pH values to-
gether with the UV-VIS and EPR spectra were monitored
during the reaction course at regular intervals. The UV-VIS
spectra were recorded after dilution of samples from the re-
action mixtures with distilled water to 6.25 × 10
−5 Ml i g a n d
concentration. The EPR spectra of frozen samples (100–270
K) of the reaction systems were recorded without dilution.
2.1. Syntheses
2.1.1. Preparationofcis-[Pt(NH3)2(Hp−3H)(H2O)2]·H2O(1)
Aqueous solution of diammine(diaqua)platinum(II) hy-
droxide (1.10−2 M, 0.2mmol) was added in excess to a
(0.05mmol) solution of Hp (molar ratio Pt:Hp = 4) at
permanent stirring. A solution of 5 × 10
−2 MK O Hw a s
added immediately until pH 10.8–11.0 is obtained. Dur-
ing this period, the acidity of the reaction solution de-
creases further spontaneously, and at pH ∼ 8, the com-
plex [Pt(NH3)2(Hp−3H)(H2O)2]·H2O 1 precipitates as a
dark-violet powder. The powder was ﬁltered, washed with
water and alcohol, and dried over P4O10. Yield is 8.4mg
(19%). Water and ammonia were determined thermogravi-
metrically. The mass losses of 2.02%, 4.16%, and 3.67%
in the temperature ranges 95–130◦C, 130–260◦C, and 260–
295◦C, respectively, correspond to 1H2O molecule, 2H2O
molecules, and 2NH3 molecules per mol of the complex
(theoretical contents 2.05%, 4.10%, and 3.88%, resp.). For-
mula C34H47N6O9Pt (878.8): Anal. Calc. C 46.46, H 5.39, N
9.56, Pt 22.19, found C 46.51, H 5.48, N 9.62, Pt 22.38%.
IR (cm−1): 3303 ν(=NH); 3235, 3218, 3172, 3093 νas,s(NH3);G. Gencheva et al. 3
2964, 2924, 2855 νas,s(CH3,C H 2); 1552, 1407 νas,s(COO−).
UV-Vis (8.10−5 M in concentrate CH3COOH) λmax(log):
395 (4.87), 510 (3.86), 545 (3.92), 565 (3.90), 630sh (3.53).
2.1.2. Preparationof[Pt(Hp−3H)(H2O)2]·H2O(2)
A procedure similar to that described for 1 was used for
the preparation of the complex 2, but the aqueous solu-
tionofdiammine(diaqua)platinum(II)hydroxide(1.10−2 M,
0.1mmol) was added in twofold excess (molar ratio Pt:Hp =
2) and a pH value of 10.3–10.5 was obtained. The complex
with composition [Pt(Hp−3H)(H2O)2]·H2O 2 was isolated
as a dark-violet precipitate by adding 3mL 0.2M HNO3.T h e
precipitate was ﬁltered, washed with water and alcohol, and
dried over P4O10. Yield is 34.6mg (82%). The water con-
tent of the complex was found thermogravimetrically. The
mass losses of 2.00% in the temperature range 100–130◦C
and 4.25% in the temperature range 130–250◦C correspond
to 1H2O molecule and 2H2O molecules (theoretical con-
tents of 2.13% and 4.26%, resp.). Formula C34H41N4O9Pt
(844.8): Anal. Calc. C 48.33, H 4.89, N 6.63, Pt 23.09, found
C 48.26, H 4.79, N 6.70, Pt 23.15%. IR (cm−1): 2968, 2915,
2875, 2820sh νas,s(CH3,C H 2); 1704 ν(−C=O); 1563, 1352,
νas,s(COO−). UV-Vis (8.10−5 M in concentrate CH3COOH)
λmax (log): 400 (4.89), 520 (3.92), 560 (3.97), 635 sh (3.56);
(8.10−5 Mi nD M F )λmax(log): 405 (4.88), 515 (3.94), 540
(3.94), 630 sh (3.49).
2.1.3. Preparationof[Pt((O,O)Hp−2H)Cl(H2O)3](3)
Aqueous solution of K2PtCl4 (0.0208g, 0.05mmol) and a
solution of Hp (0.05mmol) were mixed in equimolar ratio
(Pt:Hp = 1) and the basicity of the reaction mixture was ad-
justed to pH = 11.5 by addition of 5×10
−2 M KOH. The sys-
tem was kept at ambient temperature for 2 weeks. A dark vi-
olet complex with composition [Pt((O,O)Hp−2H)Cl(H2O)3]
was precipitated with 2mL 0.2M HClO4. Yield is 40.1mg
(97%). The water content of the complex was found thermo-
gravimetrically. The mass losses in the temperature ranges
100–161◦C (4.09%) and 225–250◦C (2.04%) correspond to
2H2Oa n d1 H 2O molecules (theoretical contents 4.09% and
2.04%, resp.). A mass loss of 4.14% observed in the tem-
perature range 160–225◦C corresponds to removal of Cl− as
HCl (theoretical 4.14%). Formula C34H42N4O9PtCl (881.2):
Anal. Calc. C 46.34, H 4.80, N 6.36, Pt 22.14, Cl 4.02%,
foundC46.66,H4.72,N6.69,Pt22.26,Cl,4.33%.IR(cm−1)
3319 ν(=NH); 2984, 2913, 2862 νas,s(CH3,C H 2); 1620, 1350,
νas,s(COO−). UV-Vis (8.10−5Mi nD M F )λmax (log): 375
(4.04) 410 (4.89), 520 (3.83), 560 (3.74), 590 (3.70), 635
(3.57).
2.2. Analysesandphysicalmeasurements
C, H, N, and Cl− analyses were performed in the Elemen-
tal Analyses Laboratory in the University of Soﬁa. The Pt
content was determined gravimetrically after treatment of
the sample with concentrate H2SO4 and 30% H2O2.Ap H -
meter Radelkis OP-208 was used for the potentiometric
measurements. The thermogravimetric measurements were
performed on TGS-2 “Perkin Elmer” system and DSC was
performed on 2C “Perkin Elmer” DS Calorimeter under ar-
gon.
2.3. Spectroscopyandmagneticmeasurements
The absorption electronic, reﬂectance, and IR spectra (KBr-
disks,4000–400cm−1,CsI-disk,400–50cm−1)wererecorded
on a UV-Vis “Carl-Zeiss, Jena,” Lambda 17 UV-VIS, and
FTIR-Bruker IFS 113V and “Perkin Elmer 983” spectrome-
ters, respectively. The EPR spectra were obtained on an X-
band “Bruker B-ER 420” spectrometer in the temperature
range 100–298 K. Magnetic susceptibility was measured be-
tween 2K and 300K in magnetic ﬁeld of 1 and/or 5 keys
using commercial SQUID magnetometer (Quantum Design
MPMS-XL) with sensitivity of 10−7 emu. The data were cor-
rected for the diamagnetic response of the sample holder
and for the diamagnetic contribution of the sample (Pas-
cal’s constants). X-ray photoemission spectra were recorded
on an ESCALAB-MkII (VG Scientiﬁc) electron spectrome-
ter ESCALAB-MkII (VG Scientiﬁc) with a base pressure of
1.10−8 Pa. C1s, O1s, N1s and Pt4f-photoemission lines were
excited with an MgKα-radiation. All XPS spectra were cali-
brated using the C1s-core level at 285.0eV as a reference.
2.4. Pharmacology
2.4.1. Celllinesandcultureconditions
Inthisstudy,thefollowinghumancelllineswereused:SKW-
3 (DSMZ no.: ACC 53)—T-cell leukemia—a derivative of
KE-37 established from a patient with acute lymphoblastic
leukemia; BV-173 (DSMZ no.: ACC 20)—chronic myeloid
leukemia established from a CML patient in a lymphoblastic
crisis; LAMA-84 (DSMZ no.: ACC 168)—chronic myeloid
leukemia, originating from a CML patient in myeloid cri-
sis. The cell lines were obtained from the German Collec-
tion of Microorganisms and Cell Cultures (DSMZ GmbH,
Germany). The cells were grown as suspension-type cul-
tures in controlled environment–RPMI-1640 medium, sup-
plemented with 10% FBS and 2mM L-glutamin, in cell cul-
tureﬂasksat37◦Cwithhumidiﬁedatmosphereand5%CO2.
Cells were refereed with fresh medium two or three times a
week in order to maintain logarithmic growth.
2.4.2. Cytotoxicityassessment,dataprocessing,and
statistics
The cell viability was assessed using the standard MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide) reduction assay as described by Mosmann [36]w i t h
minor modiﬁcations [37]. Stock solutions of cis-platin and
the new platinum complexes were freshlyprepared in DMSO
and then diluted with corresponding growth medium. At the
ﬁnal dilutions, the solvent concentration never exceeded 1%.
2.4.3. Apoptosisinductiondetection
Horizontal gel-electrophoresis of cytosolic DNA, isolated
from SKW-3 cells treated with [Pt(Hp−3H)(H2O)2], 2 was4 Metal-Based Drugs
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Figure 1: (A) Electronic absorption spectra of (a) aqueous alkaline solution of Hp; (b) 5 minutes after mixing of diammine(diaqua) plat-
inum(II)hydroxide with the ligand (Pt:Hp = 2); (c) 2 days later; (d) 2 weeks later, at the end of the reaction; (e) after addition of 2M HNO3.
(B) (a)–(c) Change of the electronic absorption spectra in the course the reaction K2PtCl4—hematoporphyrin (Pt:Hp = 1).
performed in order to test the ability of the compounds
under investigation to trigger programmed cell death
(apoptosis).The procedurewascarriedoutasdescribed else-
where [37].
The DNA fragmentation was monitored by a “Cell Death
Detection” ELISA (Roche Diagnostics GmbH, Germany) as
well. Cytosolic fractions of 1×104 c e l l sp e rg r o u p( t r e a t e do r
untreated) were used as antigen source in a sandwich ELISA,
applying primary antihistone antibody-coated microplate
and a secondary peroxidase-conjugated anti-DNA-antibody.
The photometric immunoassay for histone-associated DNA
fragments was executed according to the manufacturers in-
structions at 405nm, using ELISA reader (Unican Titertec).
The results are presented as the oligonucleosomal enrich-
ment factor EF(%): EF(%) = (ATR/ACO) × 100, where ATR
is 405nm absorption of treated samples; ACO is 405nm ab-
sorption of control samples.
3. RESULTS AND DISCUSSION
3.1. SolutionchemistryofthePt(II)-hematoporphyrin
interaction
The Pt(II)-hematoporphyrin IX interaction was stud-
ied in aqueous-alkaline solution and aerobic condi-
tions on light. The ligand for the syntheses was dis-
solved in 5 × 10
−2 M KOH. Water solutions of cis-
diammine(diaqua)platinum(II)hydroxide (obtained from
cis-platin after precipitation of Cl−)a n dK 2PtCl4 were used
as initial Pt(II) complexes. The pH value of the reaction sys-
tems, obtained at diﬀerent metal-to-ligand ratios was ad-
justed in the range 10.5–11.5 by addition of 5×10
−2 MK O H
solution.Inallcasesstudied,thePt(II)–hematoporphyrinin-
teraction started with an increase of the acidity (ΔpH = 2–
4). The changes in the electronic absorption spectra (Soret
and Q-bands) during the interactions are depicted on Fig-
ures 1(A) and 1(B).
The mixing of hematoporphyrin with diammine(di-
aqua)platinum(II)hydroxideat metal excess (Pt:Hp ≥ 2)
is connected with a slight hypsochromic shift of the Soret
band (369nm) in comparison with the free ligand spec-
trum (374nm) (Figure 1(A)a, b). Further spectral changes
(Figure 1(A)c, d) in the course of the reaction followed the
drop of the pH value. The Soret band (376nm) decreased
and broadened and a shoulder at ∼ 400nm arose. A new
band with growing intensity appeared at 270nm during the
interaction (Figure 1(A)c, d). At the end of the reaction, all
absorption bands underwent a red shift and became less in-
tensive and an additional decrease of pH value to ∼ 7.5 was
established. A sequence of IV > III > II > I for the satellite
Q-band intensity is observed. These spectral changes suggest
that the porphyrin ring in the reaction product is distorted,
and hence formation of sitting-atop- (SAT-) type complex
with an asymmetrical coordination of the ligand through
two adjacent pyrrole N atoms is most probably realized
[25, 38].
The reaction system was studied in a parallel way by
EPR measurements. A narrow signal with parameters typi-
cal for a free radical (ΔHpp ∼ 3G ,w i t hg = 2.009 ± 0.001)
was recorded in the EPR spectrum of a frozen sample takenG. Gencheva et al. 5
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Figure 2: Frozen solution EPR spectra (at 130K) of the reaction systems during the course of the interaction of (A) cis-
diammine(diaqua)platinum(II)hydroxide—Hp (Pt:Hp ≥ 2), spectra taken after (a) three hours after mixing of the reagents; (b) nine hours;
(c) a day; (d) one week; (e) two weeks, at the end of the reaction; (B) PtCl
−2
4 -Hp (Pt:Hp = 1).
one hour after the mixing of the reagents. The signal re-
mains unchanged for a week in these conditions and in-
dicates that a redox process takes also place in the system.
Several hours after the start of the reaction together with
the ﬁrst signal, a new one appeared with increasing inten-
sity (Figure 2(A)b, c). Nine superhyperﬁne lines due to the
interaction of the unpaired electron of Pt(III) with four 14N-
nuclei (I = 1) were readily observed in the perpendicular re-
gion (Figure 2). The signal most probably corresponds to a
rhombic symmetry as follows from the slight splitting ob-
served in the perpendicular region (Figure 2(A)d). A week
later, an intensive signal with parameters closed to the for-
meronecouldbeonlyfoundinthespectrum(Figure 2(A)e).
This signal corresponds to an axial symmetry of the com-
plex with g  > g⊥ > 2.0023 and g(dz2)
1 ground state. Nine
superhyperﬁne lines from four 14N-nuclei (I = 1, A⊥(N) =
21.0 × 10−4 cm−1) were observed in the perpendicular re-
gion. The superhyperﬁne structure in the parallel region due
to 14N( A  (N) = 24.9 × 10−4 cm−1) overlaps the hyperﬁne
structure due to 195Pt(I = 1/2, A  ∼ 50 × 10−4 cm−1). The
hyperﬁne structure (A(Pt)) was better resolved in the par-
allel region than in the perpendicular one (A⊥(Pt) ∼ 60 ×
10−4 cm−1). Hence, a stable Pt(III) complex is the product
of the cis-diammine(diaqua)platinum(II)hydroxide interac-
tion with hematoporphyrin in aqueous alkaline medium,
in which complex platinum(III) is surrounded by four N
donor atoms (Figure 2(A)e). The axial signal symmetry is
in accordance with the symmetrical coordination of the lig-
and to Pt(III) via the four pyrrole N-atoms in the porphyrin
macrocycle.
An intermediate Pt(III) complex with a lower symme-
try signal was recorded in the course of this reaction. In this
complex, platinum(III) is coordinated again to four nitrogen
atoms. The lower symmetry is most probably due to a SAT
complex formation where two of the nitrogens come from
adjacent porphyrin pyrroles and the other two from the am-
mine groups of the initial Pt(II) complex.
The interaction of PtCl
−2
4 with Hp in aqueous al-
kaline solution was studied at equimolar ratio of the
reagents. It was found that the acidity of the reac-
tion mixture increases faster than in the case when di-
ammine(diaqua)platinum(II)hydroxide was used. During
the reaction course, the intensity of the characteristic ab-
sorption bands decreased (Figure 1(B)a–c). A narrow EPR
signal (ΔHpp ∼ 8G)withg = 1.986 was recorded in the
EPR spectra of the frozen reaction system (130K) again due
to a stable free radical (Figure 2(B)). In addition, a second
broad (ΔHpp ∼ 60G) and low intensive signal appeared
in a magnetic ﬁeld about 3280G (g ∼ 2.06) several hours
later most probably due to a Pt(III)-complex formation. In
the spectrum, no superhyperﬁne splitting from 14Nw a so b -
served, and hence the ligand in this complex is coordinated
through the carboxylic acid groups outside the porphyrin
macrocycle.6 Metal-Based Drugs
Table 1: Thermogravimetric and calorimetric data for the complexes 1, 2,a n d3.
Complex ∗Processes of decomposition Temp. interval (◦C) E (kcal·mol−1) Thermal eﬀects
cis-[Pt(NH3)2(Hp−3H)(H2O)2]·H2O, 1
I 95–130 23.3 for 3H2O Endo
II 130–260 Endo
III 260–295 53.4 for 2NH3 Endo
[Pt(Hp−3H)(H2O)2]·H2O, 2 IV 100–130 35.9 for 3H2O Endo
V 130–250 Endo
[Pt((O,O)Hp−2H)Cl(H2O)3], 3
VI 100–161 76.0 for 2H2O Endo
VII 161–225 19.3 for 1HCl Exo
VIII 225–250 9.3 for 1H2O Endo
∗ Processes of thermal decomposition:
(I) cis-[Pt(NH3)2(Hp−3H)(H2O)2]·H2O → cis-[Pt(NH3)2(Hp−3H)(H2O)2]+H 2O
(II) cis-[Pt(NH3)2(Hp−3H)(H2O)2] → cis-Pt(NH3)2(Hp−3H)+2 H 2O
(III) cis-Pt(NH3)2(Hp−3H) → Pt(Hp−3H)+2 N H 3
(IV) [Pt(Hp−3H)(H2O)2]·H2O → [Pt(Hp−3H)(H2O)2]+H 2O
(V) [Pt(Hp−3H)(H2O)2] → Pt(Hp−3H)+2 ( H 2O)
(VI) [Pt((O,O)Hp−2H)Cl(H2O)3] → [Pt((O,O)Hp−2H)Cl(H2O)] + 2H2O
(VII) [Pt((O,O)Hp−2H)Cl(H2O)] → [Pt((O,O)Hp−3H)(H2O)] + HCl
(VIII) [Pt((O,O)Hp−3H)(H2O)] → Pt((O,O)Hp−3H)+H 2O
3.2. Structuralcharacterizationofthecomplexes
Three diﬀerent Pt(III)-hematoporphyrin complexes have
been isolated during the interactions discussed above.
The neutral complex cis-[Pt(NH3)2(Hp−3H)(H2O)2]·H2O
1 was precipitated from the reaction mixture of cis-
diammine(diaqua)platinum(II) hydroxide and hematopor-
phyrin (Pt:Hp = 4) after a spontaneous decrease of pH down
to 8. The complex [Pt(Hp−3H)(H2O)2]·H2O 2 is the main
product from the reaction mixture at Pt:Hp = 2m o l a rr a t i o .
The complex [Pt((O,O)Hp−2H)Cl(H2O)3] 3 was obtained
from the reaction system PtCl
−2
4 -Hp taken in equimolar ra-
tio. The complexes 2 and 3 were isolated as powders af-
ter addition of HNO3 and HClO4. The contents of water
and NH3 for complex 1 and of Cl− for complex 3 were de-
termined by thermogravimetric and calorimetric measure-
ments (Table 1). The relatively high temperatures of dehy-
dration(above130◦C)aswellasthethermaleﬀectsindicated
that some water molecules are bound in the inner coordina-
tion sphere. The processes of the removal of water and am-
monia molecules are endothermic, while that for Cl− as HCl
is an exothermic one.
The bands in the UV-V is absorption and reﬂectance
spectra of the complexes obtained correspond to those from
the electronic spectra recorded in the solution during the in-
teractions (Figure 1). The three Pt(III)-Hp complexes have
shown the characteristic Soret band about 400nm with a
molar absorptivity up to 1 × 105 mol−1.L.cm−1. In the spec-
trum of the complex 1, the Soret band is broadened. Four
Q-bands could readily be distinguished in the range of 500–
650 nm. The intensity of the bands IV < III ∼ II > I dif-
fersfromtheetio-type freeligandspectrumandallbandsare
red-shiftedincomparisonwiththefreeligandspectrum.The
presenceofallfourbandsindicatesarelativelylowsymmetry
oftheporphyrinring,duetoanunsymmetricalcoordination
of the hematoporphyrin ligand to platinum as it could be ex-
pected for SAT-type complexes [25, 38]. The isolation of the
complex 2 by adding of acid resulted in a reduction of the
number of the Q-bands to two (Figure 1(A)e). A decrease of
the Q-bands number was observed in the electronic and re-
ﬂectance spectra of the isolated complex. This fact could be
explained with increasing of the symmetry of the porphyrin
ringthroughcoordinationofplatinumtothefourpyrroleni-
trogen atoms. The complex 3 showed absorption spectrum
of an etio type similar to that of the free ligand with a se-
quence of the Q-bands intensity of IV > III > II > I. In addi-
tion, a shoulder at 375nm also appeared. The spectrum ob-
tained indicates that platinum is most probably coordinated
to the peripheral carboxylic groups of the hematoporphyrin
ring.
The powder EPR spectra of the complexes are shown
on Figure 3. The parameters determined from the experi-
mental spectra and those used in the simulation procedure
are shown in Table 2. The complex 2 shows (Figure 3(A)a)
an anisotropic signal (g  = 2.113 and g⊥ = 2.038) with
temperature-dependent intensity, which is due to Pt(III).
The signal possesses an axial symmetry with g  >g ⊥ > 2.003
and (dz2)
1 ground state. Nine superhyperﬁne lines due to in-
teraction of uncoupled electron with four 14N( I= 1) were
observed both in perpendicular and parallel regions. The
hyperﬁne signal structure due to 195Pt (I = 1/2) overlaps
the superhyperﬁne structure and is better resolved in the
parallel region. Simulated EPR spectrum (Figure 3(A)b) was
obtainedusingtheparametersoftheexperimentalEPRspec-
trum (Figure 3(A)a). The model is based on the assumption
that platinum is in oxidation state +3 (I = 1/2), with natu-
ral abundance of 195Pt 33.8%. Platinum(III) is assumed to
be coordinated via four nitrogens of the porphyrin macro-
cycle [39]. Nitrogen nuclei (14N, I = 1) are present in two
groups of magnetically equivalent nuclei, each group con-
taining two opposite nitrogen nuclei from the porphyrin
cycle. The simulation procedure was performed by varia-
tion of the principal values of g-tensor, nuclear hyperﬁne
tensors (A(Pt)), and nuclear superhyperﬁne tensors (A(N)).
The best ﬁt was achieved with the parameters shown in
Table 2.G. Gencheva et al. 7
Table 2: EPR parameters from the experimental spectra and parameters used in the simulation procedure.
Complexes
cis-[Pt(III)(NH3)2(Hp−3H)(H2O)2]·H2O 1
g1 g2 g3 A1(N) ×10
−4 cm−1 A2(N) ×10
−4 cm−1 A3(N) ×10
−4 cm−1
2.126 2.024 2.019 20.1 22.7 23.1
[Pt(III)(Hp−3H)(H2O)2]·H2O 2
g  g⊥ A (Pt) ×10
−4 cm−1 A⊥(Pt) ×10
−4 cm−1 A (N) ×10
−4 cm−1 A⊥(N) ×10
−4 cm−1
2.113 ±0.001 2.038 ±0.001 47.92 ±0.03 55.41 ±0.03 14.80 ±0.03 14.90 ±0.03
[Pt((O,O)Hp−2H)Cl(H2O)3] 3
g1 g2 g3 g  (radical) g⊥ (radical)
2.111 2.065 2.046 2.000 1.980
Table 3: Selected data from X-ray photoemission spectroscopy.
Compounds Pt 4f7/2 [ e V ] N1 s[ e V ] A s s i g n m e n t O1 s[ e V ]
Hematoporphyrin IX 400 >N−H 532.2
398 =N−
cis-[Pt(III)(NH3)2(Hp−3H)(H2O)2]·H2O 1 73.2
400.5 NH3
532.6 399.2 >N−Pt
398.4 >NH···N
|
=
[Pt(III)(Hp−3H)(H2O)2] ·H2O 2 73.1 399.0 >N−Pt 532.6
[Pt((O,O)Hp−2H)Cl(H2O)3] 3 73.8 400.3 >NH·········N
|
= 532.5
529.0
The EPR signal of complex 1 is anisotropic but with a
lower symmetry and an additional splitting in the perpen-
dicular region. Nine superhyperﬁne lines due to the interac-
tionwithfour 14N nuclei wereobserved. In thecaseof rhom-
bic symmetry and presence of superhyperﬁne coupling with
four 14N nuclei, the number of lines increases and the in-
tensity of the superhyperﬁne lines from 195Pt nuclei (33.8%)
decreases. Hence, the principal values of nuclear hyperﬁne
tensor (195Pt) could not be determined from the experi-
mental spectrum. The analysis of the signal was based on
the assumption for a rhombic symmetry. The values of the
rhombic g-tensor and rhombic nuclear superhyperﬁne ten-
sor A(N) were determined from the experimental spectrum
(Table 2).Thedecreaseofthesymmetryismostprobablydue
to the coordination of unequivalent N atoms in the Pt equa-
torial plane of platinum.
The EPR spectrum of complex 3 consists of two signals.
The lowﬁeld signal corresponds to Pt(III) complex with a
rhombic symmetry and g-values given in Table 2. The EPR
linewidth is close to the hyperﬁne splitting constant, and for
this reason the hyperﬁne structure from 195Pt is not resolved.
The absence of a superhyperﬁne structure from 14N nuclei
could be related to the fact that Pt(III) is coordinated outside
theporphyrinring.Thehighﬁeldsignalcorrespondstoafree
radical with an axial symmetry and parameters g  = 2.000
and g⊥ = 1.980.
Magnetic susceptibility (χ) decreases monotonically with
increasing temperature (Figure 4), thus suggesting para-
magnetic behavior in the range of 2–300K and octahe-
dral structure for all complexes studied. The eﬀective mag-
netic moments, μeﬀ, were estimated taking into account the
diamagnetic corrections via the tabulated Pascal constants
(4.08 × 10
−4 emu/mol; −3.72 × 10
−4 emu/mol; and −3.98 ×
10
−4 emu/mol for complexes 1, 2,a n d3, resp.). The calcu-
lated values of μeﬀ = 2.19μB,1 .54μB and 1.73μB, for the
complexes 1, 2,a n d3, respectively, are in an agreement with
the spin-only value μso = 1.73.
Selected data from the X-ray photoemission spectra of
the free ligand and the complexes studied are present in
Table 3. The two peaks for the N 1s binding energy at 400.0
and 398eV in the free ligand spectrum are usually assigned
to the pyrrole (H−N<) and the aza (−N=) nitrogens. The
higher energy peak belongs to the pyrrole nitrogens because
of their higher electronegativity [24].
The presence of only one N 1s peak in complex 2 indi-
cates that all nitrogens in this compound are equivalent. The
intermediate value of the N 1s binding energy (399.0eV) is
duetocoordinationofthefourNatomstoplatinumandfor-
mation of metalloporphyrin-type complex by incorporation
of platinum in the porphyrin ring.
Three diﬀerent peaks could be distinguished in the N
1s spectrum of complex 1. The two lower energy peaks at
399.2eV and 398.4eV were assigned to two pairs of equiv-
alent hematoporphyrin nitrogens. The N 1s binding energy
peak at 399.2 is assigned to nitrogens coordinated to plat-
inum. The lowest energy peak that is close to that of the free
ligand aza nitrogens is assigned to uncoordinated hemato-
porphyrin nitrogens. The equivalence of these two nitrogens
as well as the decrease of their electronegativity in compari-
son with the free pyrrole nitrogens could be explained with
delocalization of electron density by H-bonding formation
(Scheme 1). The highest binding energy peak at 400.5eV8 Metal-Based Drugs
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Figure 3: EPR spectra of polycrystalline samples of the complexes:
(A) [Pt(III)(Hp−3H)(H2O)2]·H2O 2 (298K) : (a) experimental; (b)
simulated; (B) cis-[Pt(III)(NH3)2(Hp−3H)(H2O)2]·H2O 1 (130K);
(C) [Pt((O,O)Hp−2H)Cl(H2O)3] 3 (110K).
shows the presence of nitrogens with a higher electronegativ-
ity with respect of the free ligand nitrogens and was assigned
to coordinated ammine nitrogens.
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Figure 4: Plots of the molar magnetic susceptibility (χ) versus tem-
perature for the complexes: (A) cis-[Pt(III)(NH3)2(Hp−3H)(H2O)2]
·H2O 1; (B) [Pt(III)(Hp−3H)(H2O)2]·H2O 2; (C)[Pt((O,O)Hp−2H)
Cl(H2O)3] 3.
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The coordination of the ligand by peripheral carboxylic
groups in complex 3 was proved by the presence of low en-
ergy peak in the O 1s spectrum at 529.0eV. The peaks in the
interval of 532.2–532.6eV for the free ligand and the com-
plexes O 1s spectra are due to uncoordinated ligand oxygens
and the presence of water molecules. The peak at 400.3eV
in the N 1s spectrum of complex 3 is assigned to the four
equivalent uncoordinated hematoporphyrin nitrogens. The
relativelyhighN1sbindingenergyandtheequivalenceofthe
four nitrogens could be considered as a result of a signiﬁcant
metal to ligand electron-density transfer and delocalization
by H-bonding formation (Scheme 2).
The Pt 4f spectra of the complexes are resolved into spin-
orbit pairs with splitting of 3.3eV for all complexes studied.
The determined Pt 4f7/2 binding energies values for the three
complexes in the range of 73.1–73.8eV are in accordance
with the formation of the +3 oxidation state.G. Gencheva et al. 9
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The IR data (Table 4) have shown identical ν(OH) and
νas,s(CH3,CH2) stretching vibrations for the hydroxyethyl,
methyl, and propionic side chains as well as in-plane and
out-of-plane porphyrin skeletal vibrations. The coordina-
tion of H2O in the complexes follows from the presence of
νas,s(H2O) in the range of 3350–3450cm−1and of δ(H2O) at
1600–1630cm−1. The assignments of the bands are made in
accordance with the IR data and NCA published for metallo-
porphyrins [40].
The ν(NH) band at 3312cm−1 disappears in the
spectrum of 2, and thus indicates a metal insertion
into the porphyrin macrocycle and the formation of the
metalloporphyrin-type complex. Bands of carboxylate ion
(νas,s(COO−) 1563, 1352) and carbonyl stretch (1704cm−1)
from the protonated COOH are present in the same spec-
trum. This fact shows that both protonated and deproto-
nated carboxylic groups participate in the complex. The
coordination via pyrrole N-atoms is supported also by
the presence of a strong absorption band at 441cm−1 as-
signed to Pt−N stretching vibrations. The bands in the far-
infrared spectrum in the range 390–230cm−1 were assigned
to stretching Pt−O and deformation mode vibrations of the
coordinated H2Om o l e c u l e s[ 40].
Conversely, in the IR spectrum of 3, the pres-
ence of ν(NH) at 3319cm−1 shows coordination out-
side the porphyrin macrocycle. In addition, a shift of
the C=O porphyrin-carboxylic acid bands at 1620 and
1350cm−1 indicates coordination through side chain de-
protonated carboxylic groups. A value of 270cm−1 for Δ
= (νas(COO−)−νs(COO−) proves unidentate coordination
[40]ofthecarboxylicgroups.Thebandsat366and324cm−1
aswellasthoseat258and210cm−1 areassignedtostretching
vibrations of Pt−O’ (O’ belongs to coordinated carboxylic
groups) and Pt−Cl. Other far-infrared bands at 483, 461,
453, 388, and 231 could be assigned to stretching Pt−Oa n d
deformation mode vibrations of the coordinated in-plane
and in axial positions H2O-molecules [40].
The IR spectrum of 1 shows a characteristic ν(NH)
absorption band of uncoordinated pyrrole at 3303cm−1.
The C=O absorption is shifted to 1552 and 1407cm−1
for νas,s(COO−) stretching vibrations. The value of Δ =
(νas(COO−)−νs(COO−) =145cm−1correspondstothepres-
ence of deprotonated uncoordinated carboxylic groups. Be-
sides, the bands due to coordination of NH3 molecules were
observed in the range 3235–3090cm−1 and at 1605cm−1.
These spectral data correspond to a SAT complex forma-
tion, where platinum is coordinated partially to some of the
porphyrin nitrogens, part of them being still protonated.
The Pt(III) coordination sphere includes also two NH3-
molecules from the initial Pt(II)-complex in a cis-position as
follows from the presence of two pairs of antisymmetric and
symmetric stretching vibrations of Pt−N2 and Pt−N’2(N’
belongs to NH3) at 444, 425cm−1 and 394, 364cm−1 [40].
Theotherbandsintherange316–160cm−1couldbeassigned
to stretching Pt−O and deformation mode vibrations of the
coordinated H2Om o l e c u l e s .
Summarizing all experimental data obtained, it can be
concluded that the interaction between Pt(II) and Hp in
aqueous alkaline solution proceeds in a diﬀerent way de-
pending mainly on the type of the initial Pt(II) species and
the metal-to-ligand ratio. The complexation process is ac-
companied by a parallel redox process leading to formation
of Pt(III) species and organic radicals, together with a con-
siderable decrease of pH. The ﬁnal products of the overall
Pt(II)-Hp interaction are three Hp-complexes of Pt(III).
The ﬁrst SAT-type complex 1 precipitatesin alkaline
medium after spontaneous decrease of initial pH from 11
to ∼ 8, M:L molar ratio of 4, platinum being introduced as
cis-diammine(diaqua)platinum(II) hydroxide. In these con-
ditions, the protons of the carboxylate groups dissociate and
the ligand reacts as twofold deprotonated species [20]. Its co-
ordination to Pt(III) is realized through two adjacent por-
phyrinpyrrolenitrogens,substitutingonepyrrole’hydrogen.
The PtN4-unit in the coordination sphere is formed with
participation also of two NH3-molecules in a cis-position
(Scheme 1).
The metalloporphyrin-type complex 2—the main prod-
uct from the same reaction mixture but at Pt:Hp = 2m o l a r
ratio—was isolated in a solid state using HNO3 (Scheme 3).
In acidic medium, the coordinated NH3 molecules leave the
inner coordination sphere as NH+
4 and Pt(III) coordinate to
theothertwopyrrolenitrogenatomsbysubstitutionofasec-
ond proton. The complex was precipitated through protona-
tion of one of the side carboxylate groups.
The complex 3 was obtained by the reaction of
PtCl
−2
4 and hematoporphyrin in equimolar ratio. Because of
the faster base hydrolysis of PtCl
−2
4 and the Pt(III) preference
for O-donors (in comparison with Pt(II)), the coordination
here is realized via deprotonated carboxylic groups out of the
porphyrin macrocycle. The equatorial coordination plane of
platinum includes also Cl− and H2Om o l e c u l e s( Scheme 2).
AdistortedoctahedralstructurewithH2Omoleculesdis-
posed in axial position is suggested for all three complexes.10 Metal-Based Drugs
Table 4: Selected frequencies from the infrared spectra of the free ligand and Pt(III)—hematoporphyrin IX complexes (cm−1).
Hp Complex 1 Complex 2 Complex 3 Assignment
3620 3444 3445 3390 ν(OH) + νas,s(H2O)
3432
3312 3303 — 3319 ν(NH)
—
3235
—— νas,s(NH3)1 3218
3172
3093
2969 2964 2968 2984
νas,s(CH3,CH2) 2920 2924 2915 2913
2861 2855 2875 2862
2832sh 2820sh
1715 — 1704 ν(−C=O)
— 1552 1563 1620 ν(−C=O) free νas,s(COO−)
1407 1352 1350 ν(−C−O) coord.
∼ 1605 br ∼ 1630 br ∼ 1600 br δ(NH3)1 + δ(H2O)
Far-IR region
ν(MN) + ν(MN’) + ν(MO) ν(MN) + ν(MO) ν(MN’) + ν(MO) + ν(Pt−Cl)
444st 441st 483
425 461
391 452
394 366
364 388
318 366st
316 294 324st
293
269 268 258
239 231w
234 210
214 187
165
186
160
121
106
1 Complex 1
Table 5: Comparative cytotoxic activity of the investigated platinum (III) complexes 1, 2,a n d3 versus cis-DDP in a panel of human tumour
cell lines after 72 hours (MTT-dye reduction assay).
Compound IC50 value (μM)a
SKW-3 LAMA-84 BV-173
cis-DDP 10.21 ±3.41 17.42 ±1.38 10.47 ±4.6
1 39.81 ±2.17 16.46 ±1.94 15.96 ±2.05
2 37.78 ±1.15 14.68 ±2.89 15.56 ±0.72
3 21.72 ±2.66 58.55 ±6.41 32.82 ±7.01
a Arithmetic mean ± standard deviation of 6 independent experiments.
3.3. Cytotoxicactivityofthecomplexes
The experimental data from the cytotoxicity investigation
were ﬁtted to sigmoidal dose-response curves. The corre-
spondingly calculatedIC50 values are summarized in Table 5.
The novel platinum(III) complexes under investigation ex-
ertedcytotoxiceﬀectsagainstthepanelofleukaemiccelllines
in a concentration-dependent manner. Against both BV-173
and LAMA-84 cells, the compounds 1 and 2 displayed signif-
icant cytotoxic eﬃcacy with IC50 values comparable to thoseG. Gencheva et al. 11
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Figure 5: DNA-laddering, a hallmark feature of apoptosis, follow-
ing exposure of SKW-3 cells to complex 2.D N Aw a se x t r a c t e df r o m
the cytosolic fraction of SKW-3 cells following 24-hour treatment
of complex 2, at a concentration of 10μM( l a n e1 )a n d5μM( l a n e
2), versus control (0.5% DMSO treated, lane 3) and analyzed via
0.8% agarose gel electrophoresis, ethidium bromide staining, and
UV-transillumination.
of the referent cytotoxic agent cis-DDP. Furthermore, the
maximal eﬃcacy of 1 and 2 , estimated at 50μM, was supe-
rior to that of cis-platin against both LAMA-84 and BV-173.
ItisnoteworthythatdespitethediﬀerentcelltypesofLAMA-
84 (myeloid) and BV-173 (lymphoid), these lines share
the same origin, being both isolated from chronic myeloid
leukemia (CML) patients in blast crisis. Conversely, both
cell lines are characterized via the expression of the char-
acteristic for CML BCR-ABL protein, a nonreceptor tyro-
sinekinasewhoseconstitutiveactivationrendersthecellsless
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Figure 6: Enrichment of SKW-3 cytosole with histone-associated
mono- and oligonucleosomal DNA-fragments after 24-hour treat-
ment with complex 2 at concentration 12.5μM( 2), 25μM( 3), or
50μM( 4), versus the untreated control (1). Each column repre-
sents the arithmetic mean ± standard deviations of 3 separate ex-
periments.
responsive to proapoptotic stimuli, including chemotherapy
agents [41, 42]. The cytotoxicity of cis-platin, being circa
twofold less active on LAMA-84 than in BV-173 reﬂects the
well-known discrepancies of the degree of BCR-ABL expres-
sion, being more pronounced in the former cell line [41]. In
a dissimilar fashion, both 1 and 2 share practically identi-
cal potency in both cell lines, which clearly indicates that the
level of BCR-ABL expression does not aﬀect their cytotoxic-
ity signiﬁcantly.
The complex 3 was found to be far less active on mo-
lar basis against LAMA-84 and BV-173 This complex causes
50% reduction of cell viability at 2-3 times higher concentra-
tions as compared to 1 and 2. The SKW-3 cell line demon-
stratedhighersensitivitytothecomplex 3,withanIC 50 value
being twice that of cis-DDP, whereas 1 and 2 induced half-
maximal eﬀects at 2-fold higher concentrations.
The results from the apoptosis assay are depicted on
Figure 5. The detected DNA-laddering showed that the12 Metal-Based Drugs
observedcytotoxicityofthecomplex 2isatleastpartlymedi-
ated via the recruitment of the apoptotic cell signaling path-
ways in lymphoid SKW-3 cells.
In order to elucidate the proapoptotic activity of 2 in
a more quantitative manner, its ability to induce oligonu-
cleosomal DNA fragmentation was analyzed by means of
“Cell Death Detection” ELISA (Roche Diagnostics). The ob-
tainedresultshaveshownthata24-hourtreatmentofSKW-3
cells with 2 (at 12.5, 25, or 50μM) leads to a signiﬁcant en-
richment of the cytosole with histone-associated mono- and
oligonucleosomal DNA-fragments (Figure 6). These ﬁnd-
ings together with the established DNA-laddering unam-
biguously indicate that the recruitment of the programmed
cell death signaling pathways plays a pivotal role for the cyto-
toxic mode of action of the tested complex compound.
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